Cargando…

Impact of proton therapy on antitumor immune response

Radiotherapy delivered using photons induces an immune response that leads to modulation of the tumor microenvironment. Clinical studies are ongoing to evaluate immune checkpoint inhibitors in association with photon radiotherapy. At present, there is no publication on the radio-induced immune respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mirjolet, Céline, Nicol, Anaïs, Limagne, Emeric, Mura, Carole, Richard, Corentin, Morgand, Véronique, Rousseau, Marc, Boidot, Romain, Ghiringhelli, François, Noel, Georges, Burckel, Hélène
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241828/ https://www.ncbi.nlm.nih.gov/pubmed/34188135 http://dx.doi.org/10.1038/s41598-021-92942-1

Ejemplares similares

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation
por: Waissi, Waisse, et al.
Publicado: (2021)

In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response
por: Laurent, P.A., et al.
Publicado: (2020)

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer
por: Boustani, Jihane, et al.
Publicado: (2020)

IRF8-dependent molecular complexes control the Th9 transcriptional program
por: Humblin, Etienne, et al.
Publicado: (2017)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines
por: Waissi, Waisse, et al.
Publicado: (2021)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

About the Influence of PEG Spacers on the Cytotoxicity of Titanate Nanotubes-Docetaxel Nanohybrids against a Prostate Cancer Cell Line
por: Loiseau, Alexis, et al.
Publicado: (2021)

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
por: Fumet, Jean-David, et al.
Publicado: (2020)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometry
por: Daumoine, Susy, et al.
Publicado: (2023)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
por: Kalfeist, Laura, et al.
Publicado: (2022)

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
por: Barnestein, Robby, et al.
Publicado: (2022)

Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS
por: Kalfeist, Laura, et al.
Publicado: (2023)

Immunological features of coronavirus disease 2019 in patients with cancer
por: Thibaudin, Marion, et al.
Publicado: (2020)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Transcriptome analysis of T(H)2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice
por: Bruchard, Mélanie, et al.
Publicado: (2015)

Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
por: Antoni, Delphine, et al.
Publicado: (2021)

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
por: Klopfenstein, Quentin, et al.
Publicado: (2021)

Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
por: Schmitt, Antonin, et al.
Publicado: (2023)

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study
por: Isambert, Nicolas, et al.
Publicado: (2018)

Three-Dimensional Cell Culture: A Breakthrough in Vivo
por: Antoni, Delphine, et al.
Publicado: (2015)

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
por: Niogret, Julie, et al.
Publicado: (2022)

Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice
por: Pilot, Thomas, et al.
Publicado: (2020)

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC
por: Mabrouk, Nesrine, et al.
Publicado: (2023)

Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors
por: Loiseau, Alexis, et al.
Publicado: (2019)

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
por: Oster, Paul, et al.
Publicado: (2022)

Targeting coagulation to unlock antitumor immunity?
por: Galmiche, Antoine, et al.
Publicado: (2022)

Tenascin-C: Exploitation and collateral damage in cancer management
por: Spenlé, Caroline, et al.
Publicado: (2015)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
por: Mirjolet, Céline, et al.
Publicado: (2017)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
por: Lauret Marie Joseph, Elodie, et al.
Publicado: (2021)

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
por: Roussot, Nicolas, et al.
Publicado: (2023)

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells
por: Bugaut, Hélène, et al.
Publicado: (2013)

Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma
por: Burgy, Mickaël, et al.
Publicado: (2021)

Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
por: Lesueur, Paul, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i42gtojulrgig2o55oga9aq2ii